Advertisement
Advertisement
U.S. markets close in 1 hour 9 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Abbott Laboratories (ABT)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
97.82-0.90 (-0.91%)
As of 02:51PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close98.72
Open98.85
Bid97.79 x 1000
Ask97.80 x 900
Day's Range97.57 - 99.18
52 Week Range97.57 - 142.60
Volume4,139,927
Avg. Volume4,649,139
Market Cap171.304B
Beta (5Y Monthly)0.71
PE Ratio (TTM)20.42
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.88 (1.87%)
Ex-Dividend DateOct 13, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-20% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ABT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Abbott Laboratories
    Weekly Stock ListLast week was the busiest of the quarter for earnings, with many sharp stock-price moves following above- or below-consensus results or changes in guidance. Through July 26, Refinitiv noted that 133 S&P 500 companies had reported earnings, with 76% beating expectations, above the long-term average of 66%. The blended (actual for those reporting and consensus for those still to report) growth rate is 6.2%, near the 5.6% expectation and indicating the "beats" have not been robust. But the sour mood coming into the quarter is being greeted with relief that profit shortfalls and lowered guidance are not rampant. Our analysts always look for companies that boost outlooks during earnings season. Raising guidance can be a catalyst for strong returns in the quarters ahead. Here is an initial list of BUY-rated companies in Argus coverage with raised guidance or increased outlooks during the 2Q22 EPS reporting season.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
Advertisement
Advertisement